Clobetasol Emulsion Foam and Calcipotriene 0.005% Foam Combination Therapy for the Maintenance of Treatment Response in Patients with Moderate Plaque Psoriasis
Bhatia, N.; Kircik, L.
Journal of Drugs in Dermatology Jdd 17(3): 342-346
2018
ISSN/ISBN: 1545-9616 PMID: 29537452 Document Number: 17877
Optimizing combinations for psoriasis means asking patients to take control of their disease. It means balancing potency of steroids for the short-run to put out the fire and bring relief and maintaining the clearance for the long-run to reduce recurrence potential. Successful combinations are built on tolerability, ease of application, and the efficacy demonstrated by the synergy of the sum of the parts over being used separately.
Document emailed within 1 workday
Related Documents
Feldman, S.R.; Mills, M.; Brundage, T.; Eastman, W.J. 2013: A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp Journal of Drugs in Dermatology: Jdd 12(3): 300-306Menter, A.; Abramovits, W.; Colón, L.E.; Johnson, L.A.; Gottschalk, R.W. 2009: Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis Journal of Drugs in Dermatology: Jdd 8(1): 52-57
Leonardi, C.; Bagel, J.; Yamauchi, P.; Pariser, D.; Xu, Z.; Moller, A.; Osterdal, M.L.; Stein Gold, L. 2016: The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients with Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study Journal of Drugs in Dermatology: Jdd 15(8): 981-987
Kircik, L.H.; Eastman, W.J.; Gwazdauskas, J. 2013: A randomized, double-blind phase 4 study of the efficacy and safety of ethanol-free clobetasol propionate foam, 0.05%, vs vehicle foam in the treatment of chronic hand dermatitis Journal of Drugs in Dermatology: Jdd 12(3): 328-334
Kircik, L.H.; Tropmann, C. 2011: Treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% EF foam: results from an open-label study Journal of Drugs in Dermatology: Jdd 10(12): 1398-1402
Pariser, D.M.; Green, L.J.; Stein Gold, L.; Sugarman, J.L.; Lin, T.; Pillai, R. 2018: Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy Journal of Drugs in Dermatology: Jdd 17(7): 723-726
Kircik, L. 2011: Salicylic Acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis Journal of Drugs in Dermatology: Jdd 10(3): 270-273
Kircik, L.H. 2011: Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial Journal of Drugs in Dermatology: Jdd 10(8): 878-882
Sofen, H.; Hudson, C.P.; Cook-Bolden, F.E.; Preston, N.; Colón, L.E.; Colón, L.E.; Caveney, S.W.; Gottschalk, R.W. 2011: Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial Journal of Drugs in Dermatology: Jdd 10(8): 885-892
Vender, R. 2011: An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab Journal of Drugs in Dermatology: Jdd 10(4): 396-402
Stein Gold, L.; Kircik, L.H.; Pariser, D.; Sugarman, J.L.; Lin, T.; Kang, R.; Pillai, R. 2018: Rapid Onset of Action in Patients with Moderate-to-Severe Plaque Psoriasis with Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Journal of Drugs in Dermatology: Jdd 17(8): 863-868
Umar, S.A.; Bhattacharjee, P.; Brodell, R.T. 2004: Treatment of Hailey-Hailey disease with tacrolimus ointment and clobetasol propionate foam Journal of Drugs in Dermatology: Jdd 3(2): 200-203
Wang, J.-s.; Cao, P.-l.; Yin, K. 2015: Structure design of and experimental research on a two-stage laval foam breaker for foam fluid recycling Journal of Environmental Biology 36(Special Issue): 829-836
Lahfa, M.; Mrowietz, U.; Koenig, M.; Simon, J.C. 2003: Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis European Journal of Dermatology: Ejd 13(3): 261-265
Housman, T.Salam.; Mellen, B.G.; Rapp, S.R.; Fleischer, A.B.; Feldman, S.R. 2002: Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference Cutis 70(6): 327-332
Gottlieb, A.B.; Gordon, K.B.; Lebwohl, M.G.; Caro, I.; Walicke, P.A.; Li, N.; Leonardi, C.L. 2004: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis Journal of Drugs in Dermatology: Jdd 3(6): 614-624
Jarratt, M.T.; Clark, S.D.; Savin, R.C.; Swinyer, L.J.; Safley, C.F.; Brodell, R.T.; Yu, K. 2006: Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis Cutis 78(5): 348-354
Jarratt, M.; Breneman, D.; Gottlieb, A.B.; Poulin, Y.; Liu, Y.; Foley, V. 2004: Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis Journal of Drugs in Dermatology: Jdd 3(4): 367-373
Feldman, S.R.; Winkelman, W.; Baum, E.; Preston, N. 2013: Predicting improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray Journal of Drugs in Dermatology: Jdd 12(12): 1456-1460
Menter, M.A.; Caveney, S.W.; Gottschalk, R.W. 2012: Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis Journal of Drugs in Dermatology: Jdd 11(11): 1348-1354